Saving changes...

Done

Error

2018 ACCP Journal of Clinical Pharmacology Journal CE March | Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole

2018 ACCP Journal of Clinical Pharmacology Journal CE March | Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole

2018 ACCP Journal of Clinical Pharmacology Journal CE March | Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole

Xiaoyun Liu, BS, Yifan Zhang, PhD,Qian Chen, PhD, Yan Zhan, PhD, QuanrenWang, PhD,Chaoying Hu, PhD,C
Xiaoyun Liu, BS, Yifan Zhang, PhD,Qian Chen, PhD, Yan Zhan, PhD, QuanrenWang, PhD,Chaoying Hu, PhD,C
on behalf of American College of Clinical Pharmacology

$10.00 $ 10.00 $ 10.00

$ 10.00 $ 10.00 $ 10.00
$ 10.00 $ 10.00 $ 10.00
Normal Price: $10.00 $10.00

Review:

Launch date: 05 Jun 2018
Expiry Date: 01 Mar 2021

Last updated: 16 Apr 2019

Reference: 189579

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.

Description

Small-molecule pharmacotherapeutic agents represent an emerging category with important utility in disease-state management, including applications in the field of oncology. Safe and efficacious use of these agents requires an understanding of drug interaction potential, and a recognition of pharmacodynamic and pharmacokinetic implications. This activity provides insight relative to the effects of induction and inhibition on the pharmacokinetic profile of apatinib. Such information will further inform the approach to the oncology patient, deemed a candidate for small-molecule therapy.

Objectives

Objective 1:
Identify isozymes involved in the metabolic fate of apatinib.
Objective 2:
Describe the pharmacokinetic implications of combining apatinib with enzyme inducers and inhibitors.
Objective 3:
Identify factors that contribute to variations in kinetic parameters secondary to a drug-drug interaction.
Xiaoyun Liu, BS, Yifan Zhang, PhD,Qian Chen, PhD, Yan Zhan, PhD, QuanrenWang, PhD,Chaoying Hu, PhD,C

Author Information Play Video Bio

Xiaoyun Liu, BS, Yifan Zhang, PhD,Qian Chen, PhD, Yan Zhan, PhD, QuanrenWang, PhD,Chaoying Hu, PhD,C
on behalf of American College of Clinical Pharmacology

In the 1960s, a group of eminent physicians formulated the concept of an organization dedicated to a new branch of pharmacology that dealt with the effectiveness and safety of drugs in man. As a result of their efforts, the American College of Clinical Pharmacology (ACCP) was founded on September 11, 1969. Today, ACCP consists of a full spectrum of clinical pharmacology professionals from academia, industry, government and clinical settings who span the scope from research and drug development to patient-related care and who remain dedicated to advancing clinical pharmacology with the ultimate goal of enhancing patient care.

As an organization whose primary role is education, ACCP does not concentrate on any one aspect of the discipline. Rather, it seeks to address the educational needs of its diverse membership and all healthcare professionals, covering a range of topics that span the entire area of the interaction between drugs and humans. These areas include, but are not limited to, pharmaceutical chemistry, biochemistry, drug metabolism, pharmacokinetics, pharmacodynamics, pharmacometrics, pharmacogenomics clinical pharmacology practice in the outpatient and inpatient settings, human toxicology, drug interactions and clinical drug trials. The diversity of ACCP is expressed not only in the composition of its membership, but also in its leadership. Maintaining a balance of elected Regents and Officers from all pertinent professional backgrounds ensures that ACCP remains attuned to the needs of all professionals engaged in the practice of or with a strong interest in clinical pharmacology, from the research laboratory (academic and industrial) to the classroom, and from clinical trials to improved patient care.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Continuing Medical Education (ACCME)
  • 1.00 Credits
  • Accreditation Council for Pharmacy Education (ACPE)
  • 1.00 Hours -
    Exam Pass Rate: 75

Faculty and Disclosures

Joseph Bertino, PharmD, Editor-in-Chief, JCP; Owner

Joseph Bertino, PharmD, Editor-in-Chief, JCP; Owner

Bertino Consulting, has nothing to disclose.
Steven Crosby, MA, BSP

Steven Crosby, MA, BSP

Assistant Dean, Associate Professor of Pharmacy Practice, MCPHS University, who developed the continuing education portion of this activity (target audience, goals and objectives and questions with solutions), has nothing to disclose related to this educational topic.
Michael Jann, PharmD, Professor, Pharmacotherapy, Univ of North Texas System Coll of Pharmacy,

Michael Jann, PharmD, Professor, Pharmacotherapy, Univ of North Texas System Coll of Pharmacy,

Has nothing to disclose related to this educational topic.

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error